Skip to content

ECHOGO® AMYLOIDOSIS

Cardiac Amyloidosis Screening

Advanced AI for screening patients with cardiac amyloidosis 

  • FDA-cleared
  • Live in top U.S. hospitals
  • Seamless integration with echo workflows
WHY SCREENING MATTERS

Cardiac amyloidosis is severly undiagnosed

Cardiac amyloidosis remains undiagnosed and many patients experience delays before receiving a diagnosis.¹⁻⁴ Studies have shown the disease is substantially more prevalent among patients with HFpEF.⁵

2/3

Cardiac amyloidosis patients may remain undiagnosed¹⁻⁴

~14%

Estimated cardiac amyloidosis prevalence within HFpEF⁵

14

Median hospital visits before ATTR diagnosis⁶

FDA-CLEARED SCREENING

Cardiac amyloidosis flagged from a single echo scan.

EchoGo® Amyloidosis analyzes a single apical four chamber view to screen for cardiac amyloidosis, helping clinicians identify patients who may benefit from further evaluation directly from routine echocardiography.

Clinically evaluated⁷, FDA-cleared, and granted FDA Breakthrough Device Designation.
ECG-HF-2.0-clean-frame-1
TWO DISEASE PATHWAYS

Cardiac amyloidosis screening and HFpEF identification in one workflow

The same study is also analyzed by EchoGo® Heart Failure to support HFpEF identification, helping identify patients with overlapping disease risk, with no additional scanning steps required.

Workflow Integration

Built around the way echo teams already work

EchoGo® Amyloidosis findings are returned directly into existing clinical systems, allowing clinicians to review AI results alongside routine echocardiography studies with no additional workflow steps require.

ECG-HF-2.0-clean-frame-2
CUSTOMERS

See how clinicians are using EchoGo® Amyloidosis

Learn how healthcare organizations are incorporating advanced AI for cardiac amyloidosis screening into routine echocardiography workflows.

Shuster-2

Dr. Andres Schuster at University Hospitals

"We used EchoGo® Amyloidosis in both cases. Both were flagged as suggestive of cardiac amyloidosis and were subsequently confirmed positive with biopsy."

Jamal-2

Dr. Faizi Jamal at City of Hope

"That clarity has made our reports far more actionable. Referring physicians now have something concrete to act on.  We are providing information that prompts people to intervene."

CLINICALLY EVALUATED

Trained, validated and tested across 12.5k+ real-world cases.

EchoGo® Amyloidosis was validated across 18+ global sites in a large-scale international study published in the European Heart Journal. Developed by Ultromics with Mayo Clinic, it was tested with investigators at The University of Chicago Medicine and collaborators worldwide.

Performance has been evaluated in both peer-reviewed studies and real-world clinical settings.

EchoGo Amyloidosis published study results-1
ehj icon

PEER-REVIEWED

European Heart Journal

mayo-clinic-logo (1)

Clinical sites

Chicago Medicine + 18 global sites.
Independent multisite validation.

language_36dp_08063B_FILL0_wght400_GRAD0_opsz40

real-world cases

12,500+

 

In clinical evaluation under intended-use conditions, EchoGo® Amyloidosis demonstrated 84.5% sensitivity and 89.7% specificity. See FDA 510(k) K240860 for full results. 

Publications

Featured in respected journals.

  • JCF-high-res-900px
  • JASE_high-res-1000
  • JACC_Advances_exact-(2)-1
  • EHJ-high-res-1000-px
  • Life-high-res-900-px
  • nature communications
Echo workflow wide
FDA Cleared Screening

Automatically screens for cardiac amyloidosis from a single apical four chamber view.

HFpEF-product-capabilities-2-nv2
Connected insights

Studies are also analyzed for hidden HFpEF.

amyloid-card-3-v4
SUPPORTING EARLY REFERRAL

Helps identify patients who may benefit from further evaluation.

Amyloid-card-1
Seamless Intgration

Findings flagged directly within
your echo workflow.

STREAMLINED

Automated from analysis to billing.

End-to-end automated workflow, from study analysis and report delivery through to automated billing.

Speed-background-Large-Tall
SCALABLE

Built to scale across echo labs and health systems.

Cloud-based infrastructure designed to scale across echo labs, hospitals, and health systems, from one site to enterprise-wide adoption.

Scalable background Large
SECURE

Designed for secure healthcare deployment.

HIPAA compliant, Cyber Essentials certified, ISO 27001 certified, and ISO 13485 certified.

Secure-new-3
SEAMLESS

Integrated into the workflow you already run.

Connects with ultrasound systems and PACS through secure cloud infrastructure, with no disruption to how your team works.

Seamless new 3

CUSTOMER ONBOARDING

Deploy with confidence. Simple onboarding. Designed to fit your workflow.

 

FAQ

Still got questions?

Speak with a local rep in your area to learn more. Contact us.

 

  • What is EchoGo® Amyloidosis?

    EchoGo® Amyloidosis is an FDA-cleared AI screening tool designed to identify patients who may have cardiac amyloidosis and could benefit from further diagnostic testing

  • Who is EchoGo® Amyloidosis intended for?

    EchoGo® Amyloidosis is indicated for adults aged 65 years and older with heart failure undergoing echocardiographic assessment

  • How accurate is EchoGo® Amyloidosis?

    Clinical validation demonstrated 85% sensitivity, 93% specificity, and an AUROC of 0.93 across more than 12,500 cases.

  • How does EchoGo® Amyloidosis fit into existing workflows?

    Echo studies are automatically analyzed and results are returned directly into existing clinical systems with no additional scanning steps required.

  • How quickly are results available?

    EchoGo® Amyloidosis typically returns findings in less than 20 minutes, supporting review during routine echo interpretation

EchoGo® Amyloidosis 1.0 is FDA 510(k)-cleared. Rx only, for use by or on the order of a physician. Available in the United States only.

¹ González-López E et al. European Heart Journal. 2015;36:2585-2594.

² AbouEzzeddine OF et al. JAMA Cardiology. 2021;6:1267-1274.

³ Borlaug BA et al. Journal of the American College of Cardiology. 2023;81:1810-1834.

⁴ Hahn VS et al. JACC: Heart Failure. 2020;8:712-724.

⁵ Grogan M et al. Heart. 2017;103:1065-1072.

⁶ Slivnick JA, Hawkes W et al. European Heart Journal. 2025. doi:10.1093/eurheartj/ehaf387.

 

Ready to see EchoGo® Amyloidosis in practice?

Speak with a local rep in your area to learn more.